Overview

This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.

Eligibility

Inclusion Criteria:

• • Male or female, ≥18 years.
  • women \>7 drinks/week; men \>14 drinks/week.
  • meet moderate to severe AUD score for DSM-5 criteria.
  • Breath Alcohol Content (BrAC)=0.00 at each visit.
  • in good health as confirmed by medical history, physical examination and lab tests.
  • willing to adhere to the study procedures.
  • understand informed consent and questionnaires in English at an 8th grade level.

Exclusion Criteria:

• • Women who are breastfeeding or positive urine test for pregnancy.
  • clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min
  • meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses
  • medications that reduce alcohol consumption (naltrexone, disulfiram).
  • use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).
  • history of suicide attempts in the last three years.
  • current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
  • current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
  • current use of medications that may interact with probenecid.
  • history of hypersensitivity to sulfa drugs.